Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial

References

• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121, e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• Widimsky P, Wijns W, Fajadet J et al. Reperfusion therapy for ST-elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur. Heart J.31, 943–957 (2010).
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith S Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.54, 2205–2241 (2009).
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J.29, 2909–2945 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsh J. Heparin. N. Engl. J. Med.324, 1565–1574 (1991).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest119(Suppl. 1), 64S–94S (2001).
   PubMed Web of Science ®Google Scholar
• Sobel M, Fish WR, Toma N et al. Heparin modulates integrin function in human platelets. J. Vasc. Surg.33, 587–594 (2001).
   PubMed Web of Science ®Google Scholar
• Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med.346, 957–966 (2002).
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Hasselblad V, Tcheng JE et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am. Heart J.147, 457–462 (2004).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med.344, 1895–1903 (2001).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Berkowitz SD, Lincoff AM et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am. Heart J.140, 74–80 (2000).
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi M, Menozzi A et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation109, 2203–2206 (2004).
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Sadeghi HM, Effron MB et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am. J. Cardiol.96, 474–481 (2005).
   PubMed Web of Science ®Google Scholar
• Tamhane UU, Gurm HS. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin. Drug Saf.7, 809–819 (2008).
   PubMed Web of Science ®Google Scholar
• Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA292, 1555–1562 (2004).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation114, 774–782 (2006).
   PubMed Web of Science ®Google Scholar
• Doyle BJ, Rihal CS, Gastineau DA et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J. Am. Coll. Cardiol.53, 2019–2027 (2009).
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syndromes. J. Am. Coll. Cardiol.55, 2556–2566 (2010).
   PubMed Web of Science ®Google Scholar
• Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron. Artery Dis.7, 438–448 (1996).
   PubMed Web of Science ®Google Scholar
• Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J. Am. Coll. Cardiol.41(Suppl. 4), 70S–78S (2003).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Bates ER. Direct thrombin inhibitors in cardiac disease. Cardiovasc. Toxicol.3, 13–25 (2003).
   PubMedGoogle Scholar
• Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA289, 853–863 (2003).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kleiman NS, Kereiakes DJ et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA292, 696–703 (2004).
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med.355, 2203–2216 (2006).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ware JH, Bertrand ME et al. Anti-thrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA298, 2497–2506 (2007).
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med.358, 2218–2230 (2008).
   PubMed Web of Science ®Google Scholar
• Mehran R, Lansky AJ, Witzenbichler B et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet374, 1149–1159 (2009).
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G et al.; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet377, 2193–2204 (2011).
   PubMed Web of Science ®Google Scholar
• Dangas GD, Mehran R, Nikolsky E et al.; HORIZONS-AMI Trial Investigators. Effect of switching anti-thrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J. Am. Coll. Cardiol.57, 2309–2316 (2011).
   PubMed Web of Science ®Google Scholar
• Parodi G, Antoniucci D, Nikolsky E et al. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc. Interv.3, 796–802 (2010).
   PubMed Web of Science ®Google Scholar
• Witzenbichler B, Mehran R, Guagliumi G et al. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc. Interv.4, 760–768 (2011).
   PubMed Web of Science ®Google Scholar
• Dangas G, Mehran R, Guagliumi G et al.; HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J. Am. Coll. Cardiol.54, 1438–1446 (2009).
   PubMed Web of Science ®Google Scholar
• Dangas GD, Caixeta A, Mehran R et al.; Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation123, 1745–1756 (2011).
   PubMed Web of Science ®Google Scholar
• Tsujita K, Nikolsky E, Lansky AJ et al. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive anti-thrombotic therapy (from the HORIZONS-AMI trial). Am. J. Cardiol.105, 1385–1394 (2010).
   PubMed Web of Science ®Google Scholar
• Hakim DA, Dangas GD, Caixeta A et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am. Heart J.161, 391–396 (2011).
   PubMed Web of Science ®Google Scholar
• Généreux P, Mehran R, Palmerini T et al. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention7, 905–916 (2011).
   PubMed Web of Science ®Google Scholar
• Singh HS, Mehran R, Stone GW, Dangas GD. TCT-83: two-year clinical follow-up comparing eptifibatide and abciximab in patients undergoing primary percutaneous revascularization for ST-elevation myocardial infarction results from the HORIZONS-AMI trial. J. Am. Coll. Cardiol.56, B20 (2010).
   Google Scholar
• Singh HS, Dangas G, Mehran R et al. Two-year clinical results comparing abciximab vs eptifibatide in combination with 600-mg vs 300-mg clopidogrel loading dose in patients with ST-elevation myocardial infarction: results from the HORIZONS-AMI trial. Circulation122, (2010) (Abstract 17531).
   Google Scholar
• Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J.31, 2501–2555 (2010).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Neumann FJ, Schulz S et al.; ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N. Engl. J. Med.365, 1980–1989 (2011).
   PubMed Web of Science ®Google Scholar
• Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur. Heart J.31, 561–572 (2010).
   PubMed Web of Science ®Google Scholar
• Mehta SK, Frutkin AD, Lindsey JB et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ. Cardiovasc. Interv.2, 222–229 (2009).
   PubMed Web of Science ®Google Scholar
• Barthélémy O, Silvain J, Brieger D et al. Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. Catheter Cardiovasc. Interv.79, 104–112 (2011).
   PubMed Web of Science ®Google Scholar
• Verheugt FW, Steinhubl SR, Hamon M et al. Incidence, prognostic impact and influence of anti-thrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc. Interv.4, 191–197 (2011).
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation111, 2560–2564 (2005).
   PubMed Web of Science ®Google Scholar
• Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Hosp. Pract.38, 38–43 (2010).
   Google Scholar